Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2013, Issue , 2013, Pages 511-521

  Saunthararajah, Yogen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; TRANSCRIPTION FACTOR;

CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME ABERRATION; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MYELODYSPLASTIC SYNDROME; PATHOLOGY; REVIEW; SURVIVAL RATE;

AZACITIDINE; CELL PROLIFERATION; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; DNA-CYTOSINE METHYLASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; MYELODYSPLASTIC SYNDROMES; S PHASE; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 84899960103     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2013.1.511     Document Type: Review

References (0)